Moderna's Flu Vaccine Data May Support Use in Elderly

Staff at the U.S. Food and Drug Administration (FDA) have indicated that clinical data on Moderna's flu vaccine may support its use, particularly in older adults. According to a Reuters report, FDA experts assess that the findings on the vaccine's efficacy and safety in this age group are sufficient. Moderna's mRNA-based flu vaccine uses technology similar to the company's existing COVID-19 vaccine platform. A preliminary review by FDA staff shows that the vaccine enhances immune response in elderly individuals and provides protection against seasonal influenza viruses. This assessment is seen as a significant step ahead of Moderna's application to the FDA for the flu vaccine. The FDA's advisory committee is expected to hold a meeting on the matter in the coming days and provide recommendations regarding the vaccine's approval process. Moderna aims to gain a competitive advantage in the flu vaccine market. The company intends to offer a more effective option compared to traditional flu vaccines, leveraging the rapid production and adaptability advantages of mRNA technology. This is not investment advice.